Bank Of America Corp Cardiol Therapeutics Inc. Transaction History

Bank Of America Corp

$1.43 Trillion
Q3 2025

A detailed history of Bank Of America Corp transactions in Cardiol Therapeutics Inc. stock. As of the latest transaction made, Bank Of America Corp holds 551,053 shares of CRDL stock, worth $562,074. This represents 0.0% of its overall portfolio holdings.

Number of Shares

551,053

Previous 26,455 1982.98%

Holding current value

$562,074

Previous $35,000 1537.14%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	BUY	$0.99 - $1.54 $519,352 - $807,880	524,598 Added 1982.98%	551,053 $573,000
Q2 2025 Aug 14, 2025	BUY	$0.81 - $1.47 $12,356 - $22,424	15,255 Added 136.21%	26,455 $35,000
Q1 2025 May 15, 2025	SELL	$0.96 - $1.46 $288 - $438	-300 Reduced 2.61%	11,200 $10,000
Q4 2024 Feb 14, 2025	BUY	$1.25 - $2.07 $9,375 - $15,524	7,500 Added 187.5%	11,500 $14,000
Q4 2023 Feb 14, 2024	BUY	$0.67 - $1.0 $2,680 - $4,000	4,000 New	4,000 $3,000
Q1 2023 May 12, 2023	BUY	$0.47 - $0.81 $28,435 - $49,005	60,500 New	60,500 $29,000
Q3 2022 Nov 14, 2022	SELL	$1.02 - $1.41 $18,068 - $24,976	-17,714 Reduced 92.68%	1,399 $1,000
Q2 2022 Aug 12, 2022	BUY	$1.03 - $2.05 $19,686 - $39,181	19,113 New	19,113 $25,000
Q1 2022 May 16, 2022	SELL	$1.25 - $2.31 $1,625 - $3,003	-1,300 Closed	0 $0
Q4 2021 Feb 08, 2022	SELL	$1.83 - $4.86 $22,889 - $60,788	-12,508 Reduced 90.59%	1,300 $2,000
Q3 2021 Nov 15, 2021	BUY	$2.03 - $4.8 $28,030 - $66,278	13,808 New	13,808 $57,000

Others Institutions Holding CRDL

# of Institutions

Shares Held

6.11M

Call Options Held

37.6K

Put Options Held

View Full List

About Cardiol Therapeutics Inc.

Ticker CRDL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 61,942,500
Market Cap $63.2M
Description
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product is CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate t...

More about CRDL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.

Account

Bank Of America Corp Cardiol Therapeutics Inc. Transaction History